Immuron Limited · ASX:IMC
Immuron — Emerging Growth Conference (September 2024)
30 slides from Immuron's conference presentation, Sep 26, 2024
Slide 1: Investor Presentation – Steven Lydeamore, CEO
26 September 2024 Steven Lydeamore Chief Executive Officer Investor Presentation NASDAQ: IMRN ASX: IMC
Slide 2: Safe Harbor Statement
Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “ intends,” “ plans,” “ believes,” “ seeks,” “estimates,” “guidance” and s imilar expressions are intended
Slide 3: Executive summary
3 Executive summary Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases 3 as of 24 September 2024 U.S. Department of Defense Research Award for NMRC and W
Slide 4: Travelan record sales
4 Travelan® record sales Global + Full Year FY2024 AUD$4.9 million up 172% on (prior comparative period) pcp + June 2024 Quarter AUD$1.3 million up 277% on pcp and 5% on last quarter Australia + Full Year 2024 AUD$3.7 million up 236% on pcp + June 2024 Quarter AUD$1.0 million up 247% on pcp and 13%
Slide 5: Addressable market & industry overview
5 Chief Commercial Officer has 20+ year’s experience with local and global (Asia, UK) commercial leadership roles with GSK and P&G Addressable market & industry overview * IMC Company Report - Travelan Market Analysis 2019 ** Centers for Disease Control and Prevention Yellow Book North America FY24:
Slide 6: Addressable market & industry overview
6 Addressable market & industry overview Billion Dollar Market Traveller’s diarrhoea treatment market is large and growing at a CAGR of ~7% 1 Industry tailwinds Travel picking up significantly following COVID lockdowns Frequent Symptom 30% - 70% of travelers experience traveller’s diarrhoea 2 • Ther
Slide 7: Immuron's clinical programs – opportunity assessment
7 IMMURON’S CLINICAL PROGRAMS – OPPORTUNITY ASSESSMENT › Immuron’s development of IMM - 124E (hyperimmune bovine colostrum) as a prescription medication has the potential to address this unmet need › Primary care physicians (PCP)s impressed with clinical efficacy endpoint targets demonstrating > 80%
Slide 8: Technology platform
8 + Reduce occurrence and reduce/relieve diarrhoea + Reduce/relieve abdominal cramping + Reduce/relieve gastrointestinal pain + Assists repair of gastrointestinal/gut wall lining + Enhance/promote immune defence + Enhance/promote health liver function Australian Permitted indications; these statemen
Slide 9: Travelan mechanism of action
9 Pre - Clinical Studies Broad spectrum antimicrobial Travelan® | Mechanism of action With Travelan ® Bacteria neutralized by Travelan ® antibodies Without Travelan® Bacteria attach to gut wall and infect Protects against bacterial adhesion to host cell intestinal epithelia Binds to surface layer pr
Slide 10: Immuron's clinical programs
10 Market Phase III Phase II Phase I Indication Compound or brand name Travelers’ Diarrhea ETEC challenge IMM - 124E Travelan® Clostridioides difficile Infection & Recurrence IMM - 529 Market Phase III Phase II Phase I Partner Compound or brand name Uniformed Services University Travelan® Naval Medi
Slide 11: World first triple mechanism of action for CDI
WORLD FIRST TRIPLE MECHANISM OF ACTION FOR CDI IMM - 529: pre - IND filed with FDA July 2024 IMM - 529 will be indicated for the treatment of recurrent C. difficile infection Indication / Target Population • Novel antibody - containing therapeutic which neutralizes C. difficile but does not impact t
Slide 12: Positive results support Travelan
12 Positive results support Travelan® Travelan® topline clinical trial results demonstrate protective efficacy with single daily dose. progress to phase 3 IMM - 124E Phase 2 + Healthy volunteers were recruited and randomized to receive a single daily oral dose of 1200 mg of Travelan® or placebo. Dos
Slide 13: IMM-124E Phase 3 strategy
13 IMM - 124E Phase 3 strategy Phase 1 clinical study (Baltimore, 1996) Phase 2 clinical study (Poland, 2000) FDA 1 IND 2 approval (December 2022) Phase 2 clinical study (Baltimore, 2024) Additional topline data analysis August 2024 Clinical Study Report anticipated September 2024 End of Phase 2 FDA
Slide 14: Scientific references
14 Scientific references Travelan® (IMM - 124E) Scandinavian Journal of Gastroenterology, 46:7 - 8, 862 - 868, DOI: 10.3109/00365521.2011.574726 Travelan® has been shown to reduce both the incidence and severity of ETEC - induced diarrhea in up to 90% of volunteers Military Health System Research Sy
Slide 15: Contact information
EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172 STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION:
Slide 16: Investor Presentation – Steven Lydeamore, CEO
26 September 2024 Steven Lydeamore Chief Executive Officer Investor Presentation NASDAQ: IMRN ASX: IMC
Slide 17: Safe Harbor Statement
Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “ intends,” “ plans,” “ believes,” “ seeks,” “estimates,” “guidance” and s imilar expressions are intended
Slide 18: Executive summary
3 Executive summary Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases 3 as of 24 September 2024 U.S. Department of Defense Research Award for NMRC and W
Slide 19: Travelan record sales
4 Travelan® record sales Global + Full Year FY2024 AUD$4.9 million up 172% on (prior comparative period) pcp + June 2024 Quarter AUD$1.3 million up 277% on pcp and 5% on last quarter Australia + Full Year 2024 AUD$3.7 million up 236% on pcp + June 2024 Quarter AUD$1.0 million up 247% on pcp and 13%
Slide 20: Addressable market & industry overview
5 Chief Commercial Officer has 20+ year’s experience with local and global (Asia, UK) commercial leadership roles with GSK and P&G Addressable market & industry overview * IMC Company Report - Travelan Market Analysis 2019 ** Centers for Disease Control and Prevention Yellow Book North America FY24:
Slide 21: Addressable market & industry overview
6 Addressable market & industry overview Billion Dollar Market Traveller’s diarrhoea treatment market is large and growing at a CAGR of ~7% 1 Industry tailwinds Travel picking up significantly following COVID lockdowns Frequent Symptom 30% - 70% of travelers experience traveller’s diarrhoea 2 • Ther
Slide 22: Immuron's clinical programs – opportunity assessment
7 IMMURON’S CLINICAL PROGRAMS – OPPORTUNITY ASSESSMENT › Immuron’s development of IMM - 124E (hyperimmune bovine colostrum) as a prescription medication has the potential to address this unmet need › Primary care physicians (PCP)s impressed with clinical efficacy endpoint targets demonstrating > 80%
Slide 23: Technology platform
8 + Reduce occurrence and reduce/relieve diarrhoea + Reduce/relieve abdominal cramping + Reduce/relieve gastrointestinal pain + Assists repair of gastrointestinal/gut wall lining + Enhance/promote immune defence + Enhance/promote health liver function Australian Permitted indications; these statemen
Slide 24: Travelan mechanism of action
9 Pre - Clinical Studies Broad spectrum antimicrobial Travelan® | Mechanism of action With Travelan ® Bacteria neutralized by Travelan ® antibodies Without Travelan® Bacteria attach to gut wall and infect Protects against bacterial adhesion to host cell intestinal epithelia Binds to surface layer pr
Slide 25: Immuron's clinical programs
10 Market Phase III Phase II Phase I Indication Compound or brand name Travelers’ Diarrhea ETEC challenge IMM - 124E Travelan® Clostridioides difficile Infection & Recurrence IMM - 529 Market Phase III Phase II Phase I Partner Compound or brand name Uniformed Services University Travelan® Naval Medi
Slide 26: World first triple mechanism of action for CDI
WORLD FIRST TRIPLE MECHANISM OF ACTION FOR CDI IMM - 529: pre - IND filed with FDA July 2024 IMM - 529 will be indicated for the treatment of recurrent C. difficile infection Indication / Target Population • Novel antibody - containing therapeutic which neutralizes C. difficile but does not impact t
Slide 27: Positive results support Travelan
12 Positive results support Travelan® Travelan® topline clinical trial results demonstrate protective efficacy with single daily dose. progress to phase 3 IMM - 124E Phase 2 + Healthy volunteers were recruited and randomized to receive a single daily oral dose of 1200 mg of Travelan® or placebo. Dos
Slide 28: IMM-124E Phase 3 strategy
13 IMM - 124E Phase 3 strategy Phase 1 clinical study (Baltimore, 1996) Phase 2 clinical study (Poland, 2000) FDA 1 IND 2 approval (December 2022) Phase 2 clinical study (Baltimore, 2024) Additional topline data analysis August 2024 Clinical Study Report anticipated September 2024 End of Phase 2 FDA
Slide 29: Scientific references
14 Scientific references Travelan® (IMM - 124E) Scandinavian Journal of Gastroenterology, 46:7 - 8, 862 - 868, DOI: 10.3109/00365521.2011.574726 Travelan® has been shown to reduce both the incidence and severity of ETEC - induced diarrhea in up to 90% of volunteers Military Health System Research Sy
Slide 30: Contact information
EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172 STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION:
Immuron — Emerging Growth Conference (September 2024) on 6ix